Literature DB >> 27247630

Novel immunotherapeutic approaches to the treatment of urothelial carcinoma.

Akhil Muthigi1, Arvin K George1, Sam J Brancato1, Piyush K Agarwal2.   

Abstract

Immunotherapy has long played a role in urothelial cancers with the use of bacille Calmette Guérin (BCG) being a mainstay in the treatment of nonmuscle invasive bladder cancer. Novel therapeutic approaches have not significantly impacted mortality in this population and so a renaissance in immunotherapy has resulted. This includes recombinant BCG, oncolytic viruses, monoclonal antibodies, vaccines, and adoptive T-cell therapy. Herein, we provide a review of the current state of the art and future therapies regarding immunotherapeutic strategies for urothelial carcinoma.

Entities:  

Keywords:  NMIBC; immunotherapy; urothelial carcinoma

Year:  2016        PMID： 27247630      PMCID： PMC4872187          DOI： 10.1177/1756287216628784

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN： 1756-2872


  71 in total

1.  Nanoparticulation of BCG-CWS for application to bladder cancer therapy.

Authors:  Takashi Nakamura; Masafumi Fukiage; Megumi Higuchi; Akihiro Nakaya; Ikuya Yano; Jun Miyazaki; Hiroyuki Nishiyama; Hideyuki Akaza; Toshihiro Ito; Hiroyuki Hosokawa; Toshinori Nakayama; Hideyoshi Harashima
Journal:  J Control Release       Date:  2013-12-31       Impact factor: 9.776

2.  Recombinant BCG coexpressing Ag85B, CFP10, and interleukin-12 induces multifunctional Th1 and memory T cells in mice.

Authors:  Chih-Wei Lin; Ih-Jen Su; Jia-Ru Chang; Yih-Yuan Chen; Jang-Jih Lu; Horng-Yunn Dou
Journal:  APMIS       Date:  2011-10-06       Impact factor: 3.205

3.  Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guérin vaccine on bladder cancer cells.

Authors:  Guo-qing Ding; Yan-lan Yu; Zhou-jun Shen; Xie-lai Zhou; Shan-wen Chen; Guo-dong Liao; Yue Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2012-05       Impact factor: 3.066

4.  The inhibitory effects of interferon gamma on the growth of bladder cancer cells.

Authors:  S J Hawkyard; A M Jackson; K James; S Prescott; J F Smyth; G D Chisholm
Journal:  J Urol       Date:  1992-05       Impact factor: 7.450

5.  Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma.

Authors:  Padmanee Sharma; Yu Shen; Sijin Wen; Dean F Bajorin; Victor E Reuter; Lloyd J Old; Achim A Jungbluth
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

6.  Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.

Authors:  E O Haaff; S M Dresner; T L Ratliff; W J Catalona
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

7.  Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro.

Authors:  Wujiang Liu; Michael A O'Donnell; Xiaohong Chen; Ruifa Han; Yi Luo
Journal:  Cancer Immunol Immunother       Date:  2009-02-13       Impact factor: 6.968

8.  Feasibility of T-cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept.

Authors:  Amir Sherif; Mudhar N Hasan; Per Marits; Mona Karlsson; Ola Winqvist; Magnus Thörn
Journal:  Eur Urol       Date:  2009-09-11       Impact factor: 20.096

9.  Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.

Authors:  Chi-Feng Lee; Suh-Yran Chang; Dar-Shih Hsieh; Dah-Shyong Yu
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

10.  Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin.

Authors:  Sarah Young; Michael O'Donnell; Euan Lockhart; Bryce Buddle; Lynn Slobbe; Yi Luo; Geoff De Lisle; Glenn Buchan
Journal:  Immunol Cell Biol       Date:  2002-06       Impact factor: 5.126
View more
  5 in total

Review 1.  Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

Authors:  Kenneth M Felsenstein; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

2.  Cytotoxicity anticancer activities of anastrozole against breast, liver hepatocellular, and prostate cancer cells.

Authors:  Firas Hassan; Gamal A El-Hiti; Mays Abd-Allateef; Emad Yousif
Journal:  Saudi Med J       Date:  2017-04       Impact factor: 1.484

3.  BCG as a Vector for Novel Recombinant Vaccines against Infectious Diseases and Cancers.

Authors:  Abu Salim Mustafa
Journal:  Vaccines (Basel)       Date:  2020-12-04

4.  Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder.

Authors:  Anjelica Hodgson; Achim A Jungbluth; Nora Katabi; Bin Xu; Michelle R Downes
Journal:  Virchows Arch       Date:  2019-09-02       Impact factor: 4.064

Review 5.  New therapies in nonmuscle invasive bladder cancer treatment.

Authors:  Kareem N Rayn; Graham R Hale; Gustavo Pena-La Grave; Piyush K Agarwal
Journal:  Indian J Urol       Date:  2018 Jan-Mar
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.